Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis

NCT01408602 is registered in ClinicalTrials.gov with Molecular Research Center, Inc. as lead sponsor.

NCT NCT01408602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01408602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Lead sponsor
Molecular Research Center, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2011
Completion date
July 31, 2014
Enrollment
300 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis